Open an account

InMed Pharmaceuticals

MTRI · NASDAQ

$15.61+$3.41 (+27.94%)TodayMarket closed ·
Prev close $12.20

About MTRI

InMed Pharmaceuticals, Inc. engages in developing small molecule drug candidates targeting the CB1/CB2 receptors. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. The firm is focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. CB1 receptors are primarily located in the brain and central nervous system, while CB2 receptors are involved in modulating neuroinflammation and immune responses. The firm's pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer's disease, dry Age-Related Macular Degeneration, or dry AMD, and Epidermolysis Bullosa, or EB. Its INM-901 is a small molecule, disease-modifying drug developed for treatment for Alzheimer's disease. The company also offers various modes of administration, including oral delivery. Its INM-089 is a drug candidate for dry age-related macular degeneration. Its INM-755 is a cannabinol cream topical product candidate intended as a therapy in dermatological diseases.

Employees
0
Headquarters
Vancouver, British Columbia
Listed
Jun 21, 2001
Sector
Health Care
Industry
Pharmaceuticals
Website
inmedpharma.com

MTRI key statistics

Market cap
9.61M
Price-earnings ratio
-0.53
Dividend yield
—
Average volume
12.59K
Volume
44.23K
Open price
$12.50
High today
$16.50
Low today
$12.50
52 Week high
$23.30
52 Week low
$5.75

InMed Pharmaceuticals (MTRI) at a glance

As of Nov 11, 2026, InMed Pharmaceuticals (MTRI) shares are priced at $15.61, giving the company a market cap of 9.61M and a price-to-earnings ratio of -0.53.

Today the stock has traded between $12.50 and $16.50. The current price is 24.9% above the day's low and 5.4% below its high.

Volume so far is 44.23K shares, above the average of 12.59K shares a day.

Over the past year InMed Pharmaceuticals has ranged from $5.75 to $23.30, and now sits 56% of the way up that range.

InMed Pharmaceuticals met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q3 FY25 it reported -$1.94 per share against an estimate of $0.00.

The average analyst price target is $20.40, 30.7% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 2 analystsAvg $20.40
Low
$20.20
Now
$15.61
High
$21.00

MTRI earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 15.1% on average.

  1. Q4 FY21: reported -$205.00 per share against an estimate of -$171.70
  2. Q1 FY22: reported -$125.00 per share against an estimate of -$176.75
  3. Q2 FY22: reported -$155.00 per share against an estimate of -$118.68
  4. Q3 FY22: reported -$125.00 per share against an estimate of -$126.25
  5. Q4 FY22: reported -$280.60 per share against an estimate of -$111.10
  6. Q1 FY24: reported -$0.76 per share against an estimate of $0.00
  7. Q2 FY24: reported -$0.19 per share against an estimate of $0.00
  8. Q3 FY25: reported -$1.94 per share against an estimate of $0.00

MTRI news

  • Press releasePRNewswire

    InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics

Similar companies

Companies in the same industry as InMed Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.